scholarly article | Q13442814 |
P2093 | author name string | Phillips I | |
King A | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | gram-positive bacteria | Q857288 |
P304 | page(s) | 219-223 | |
P577 | publication date | 2001-08-01 | |
P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
P1476 | title | The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates | |
P478 | volume | 48 |
Q43183404 | Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid |
Q36879791 | Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection |
Q36525654 | Antibiotics for treatment of resistant gram-positive coccal infections |
Q37000729 | Antimicrobial treatment for intra-abdominal infections |
Q34939045 | Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001 |
Q42924831 | Chemical Probes of Escherichia coli Uncovered through Chemical-Chemical Interaction Profiling with Compounds of Known Biological Activity |
Q36445468 | Children hospitalized with skin and soft tissue infections: a guide to antibacterial selection and treatment |
Q38990504 | Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain |
Q87107449 | Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria |
Q35166213 | Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus |
Q35637066 | Daptomycin |
Q44768109 | Daptomycin |
Q35925535 | Daptomycin - a novel antibiotic against Gram-positive pathogens |
Q38282725 | Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections |
Q35771368 | Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus |
Q38898667 | Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus |
Q40189196 | Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria |
Q40166184 | Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis |
Q36003721 | Daptomycin: a cyclic lipopeptide antimicrobial agent |
Q36972980 | Daptomycin: a review 4 years after first approval |
Q37693931 | Daptomycin: pharmacology and clinical use. |
Q36718474 | Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections |
Q49887078 | Enterococcus faecalis and pathogenic streptococci inactivate daptomycin by releasing phospholipids |
Q33239640 | Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection |
Q46908684 | Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves |
Q40718774 | Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria. |
Q36492244 | In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants |
Q39792691 | In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis |
Q42107088 | In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection |
Q35753477 | New therapies for pneumococcal meningitis |
Q34666658 | Novel agents for resistant Gram-positive infections--a review |
Q35056042 | Novel agents for the treatment of resistant Gram-positive infections |
Q36426011 | Oritavancin--an investigational glycopeptide antibiotic |
Q45029806 | Physical and chemical compatibility of daptomycin with nine medications |
Q48300017 | Preliminary study of a controllable device for subtenon drug infusion in a rabbit model. |
Q36995920 | Telavancin: a novel lipoglycopeptide antimicrobial agent |
Q33788308 | Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens |
Q34330270 | The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections |
Q36521880 | Update on daptomycin: the first approved lipopeptide antibiotic |
Search more.